GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (STU:GXE) » Definitions » Cyclically Adjusted PS Ratio

Galapagos NV (STU:GXE) Cyclically Adjusted PS Ratio : 4.51 (As of May. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Galapagos NV Cyclically Adjusted PS Ratio?

As of today (2024-05-26), Galapagos NV's current share price is €25.16. Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €5.58. Galapagos NV's Cyclically Adjusted PS Ratio for today is 4.51.

The historical rank and industry rank for Galapagos NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:GXE' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.51   Med: 8.39   Max: 35.11
Current: 4.51

During the past years, Galapagos NV's highest Cyclically Adjusted PS Ratio was 35.11. The lowest was 4.51. And the median was 8.39.

STU:GXE's Cyclically Adjusted PS Ratio is ranked better than
55.14% of 506 companies
in the Biotechnology industry
Industry Median: 5.565 vs STU:GXE: 4.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Galapagos NV's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.948. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €5.58 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted PS Ratio Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 15.06 9.12 7.27 6.66

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.28 6.33 5.43 6.66 5.28

Competitive Comparison of Galapagos NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PS Ratio falls into.



Galapagos NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Galapagos NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=25.16/5.58
=4.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Galapagos NV's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.948/130.5518*130.5518
=0.948

Current CPI (Mar. 2024) = 130.5518.

Galapagos NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.482 0.000
201409 0.444 99.195 0.584
201412 0.680 99.086 0.896
201503 0.488 99.423 0.641
201506 0.345 100.107 0.450
201509 0.146 100.245 0.190
201512 0.184 100.572 0.239
201603 0.222 101.653 0.285
201606 0.597 102.267 0.762
201609 0.235 102.118 0.300
201612 1.721 102.614 2.190
201703 0.735 103.972 0.923
201706 0.537 103.902 0.675
201709 0.537 104.170 0.673
201712 0.773 104.804 0.963
201803 0.742 105.419 0.919
201806 0.958 106.063 1.179
201809 1.790 106.618 2.192
201812 1.775 107.252 2.161
201903 0.604 107.876 0.731
201906 1.069 107.896 1.293
201909 10.582 107.470 12.855
201912 1.629 108.065 1.968
202003 1.392 108.550 1.674
202006 1.532 108.540 1.843
202009 1.946 108.441 2.343
202012 2.389 108.511 2.874
202103 1.703 109.522 2.030
202106 2.133 110.305 2.525
202109 0.980 111.543 1.147
202112 -1.276 114.705 -1.452
202203 2.049 118.620 2.255
202206 2.094 120.948 2.260
202209 2.069 124.120 2.176
202212 -2.787 126.578 -2.875
202303 0.883 126.528 0.911
202306 4.135 125.973 4.285
202309 1.808 127.083 1.857
202312 -3.194 128.292 -3.250
202403 0.948 130.552 0.948

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (STU:GXE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Galapagos NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (STU:GXE) Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (STU:GXE) Headlines

No Headlines